Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 1.91
BIOC's Cash to Debt is ranked lower than
55% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. BIOC: 1.91 )
Ranked among companies with meaningful Cash to Debt only.
BIOC' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.03 Max: 1.91
Current: 1.91
0.01
1.91
Equity to Asset 0.35
BIOC's Equity to Asset is ranked lower than
80% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. BIOC: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
BIOC' s Equity to Asset Range Over the Past 10 Years
Min: -18.63  Med: -7.47 Max: 0.35
Current: 0.35
-18.63
0.35
F-Score: 4
Z-Score: -23.32
M-Score: 0.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -2690.33
BIOC's Operating margin (%) is ranked lower than
93% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. BIOC: -2690.33 )
Ranked among companies with meaningful Operating margin (%) only.
BIOC' s Operating margin (%) Range Over the Past 10 Years
Min: -1227100  Med: -9635.78 Max: -2690.33
Current: -2690.33
-1227100
-2690.33
Net-margin (%) -2778.69
BIOC's Net-margin (%) is ranked lower than
93% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.99 vs. BIOC: -2778.69 )
Ranked among companies with meaningful Net-margin (%) only.
BIOC' s Net-margin (%) Range Over the Past 10 Years
Min: -1362900  Med: -11247.71 Max: -2778.69
Current: -2778.69
-1362900
-2778.69
ROE (%) -241.91
BIOC's ROE (%) is ranked lower than
93% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.45 vs. BIOC: -241.91 )
Ranked among companies with meaningful ROE (%) only.
BIOC' s ROE (%) Range Over the Past 10 Years
Min: -976.38  Med: -976.38 Max: -976.38
Current: -241.91
ROA (%) -120.10
BIOC's ROA (%) is ranked lower than
89% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.96 vs. BIOC: -120.10 )
Ranked among companies with meaningful ROA (%) only.
BIOC' s ROA (%) Range Over the Past 10 Years
Min: -694.81  Med: -530.72 Max: -197.64
Current: -120.1
-694.81
-197.64
ROC (Joel Greenblatt) (%) -2047.28
BIOC's ROC (Joel Greenblatt) (%) is ranked lower than
90% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.49 vs. BIOC: -2047.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIOC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2717.73  Med: -1748.43 Max: -1307.16
Current: -2047.28
-2717.73
-1307.16
» BIOC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with BIOC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.27
BIOC's P/B is ranked lower than
75% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. BIOC: 5.27 )
Ranked among companies with meaningful P/B only.
BIOC' s P/B Range Over the Past 10 Years
Min: 2.1  Med: 4.33 Max: 9.15
Current: 5.27
2.1
9.15
P/S 24.75
BIOC's P/S is ranked lower than
84% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. BIOC: 24.75 )
Ranked among companies with meaningful P/S only.
BIOC' s P/S Range Over the Past 10 Years
Min: 7.95  Med: 37.25 Max: 90.28
Current: 24.75
7.95
90.28
Current Ratio 2.89
BIOC's Current Ratio is ranked higher than
53% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. BIOC: 2.89 )
Ranked among companies with meaningful Current Ratio only.
BIOC' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 0.07 Max: 4.13
Current: 2.89
0.02
4.13
Quick Ratio 2.78
BIOC's Quick Ratio is ranked higher than
56% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. BIOC: 2.78 )
Ranked among companies with meaningful Quick Ratio only.
BIOC' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 0.07 Max: 3.99
Current: 2.78
0.02
3.99
Days Inventory 22.32
BIOC's Days Inventory is ranked higher than
82% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.76 vs. BIOC: 22.32 )
Ranked among companies with meaningful Days Inventory only.
BIOC' s Days Inventory Range Over the Past 10 Years
Min: 9.26  Med: 16.71 Max: 23.71
Current: 22.32
9.26
23.71
Days Sales Outstanding 20.34
BIOC's Days Sales Outstanding is ranked higher than
92% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.42 vs. BIOC: 20.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.34  Med: 30.19 Max: 1825
Current: 20.34
20.34
1825
Days Payable 54.01
BIOC's Days Payable is ranked higher than
50% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.01 vs. BIOC: 54.01 )
Ranked among companies with meaningful Days Payable only.
BIOC' s Days Payable Range Over the Past 10 Years
Min: 50.27  Med: 241.40 Max: 22179.12
Current: 54.01
50.27
22179.12

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.90
BIOC's Price/Net Cash is ranked lower than
53% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.50 vs. BIOC: 9.90 )
Ranked among companies with meaningful Price/Net Cash only.
BIOC' s Price/Net Cash Range Over the Past 10 Years
Min: 13.8  Med: 13.80 Max: 13.8
Current: 9.9
Price/Net Current Asset Value 7.07
BIOC's Price/Net Current Asset Value is ranked higher than
50% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.07 vs. BIOC: 7.07 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIOC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 9.86  Med: 9.86 Max: 9.86
Current: 7.07
Price/Tangible Book 5.27
BIOC's Price/Tangible Book is ranked lower than
56% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.31 vs. BIOC: 5.27 )
Ranked among companies with meaningful Price/Tangible Book only.
BIOC' s Price/Tangible Book Range Over the Past 10 Years
Min: 7.34  Med: 7.34 Max: 7.34
Current: 5.27
Price/Median PS Value 0.67
BIOC's Price/Median PS Value is ranked higher than
76% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. BIOC: 0.67 )
Ranked among companies with meaningful Price/Median PS Value only.
BIOC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.93  Med: 1.39 Max: 1.85
Current: 0.67
0.93
1.85
Earnings Yield (Greenblatt) (%) -106.40
BIOC's Earnings Yield (Greenblatt) (%) is ranked lower than
94% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. BIOC: -106.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIOC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -560.3  Med: 0.00 Max: 0
Current: -106.4
-560.3
0

More Statistics

Revenue(Mil) $1
EPS $ -1.07
Short Percentage of Float13.55%
52-Week Range $0.94 - 3.70
Shares Outstanding(Mil)19.98

Analyst Estimate

Dec16
Revenue(Mil)
EPS($) -0.85
EPS without NRI($) -0.85
» More Articles for NAS:BIOC

Headlines

Articles On GuruFocus.com
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 

More From Other Websites
Biocept to Present at the Inaugural Joseph Gunnar PIONEERS 2016 Conference May 02 2016
Biocept to Present at the Inaugural Joseph Gunnar PIONEERS 2016 Conference May 02 2016
BIOCEPT INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Apr 29 2016
Biocept, Inc. Announces Pricing Of $5 Million Public Offering Of Common Stock And Warrants Apr 29 2016
Biocept, Inc. Announces Pricing Of $5 Million Public Offering Of Common Stock And Warrants Apr 29 2016
Biocept Inc. Announces Proposed Public Offering Of Common Stock And Warrants Apr 28 2016
Biocept Collaborates with MedStar Georgetown University Hospital for Liquid Biopsy Study Apr 27 2016
Biocept Collaborates with MedStar Georgetown University Hospital for Liquid Biopsy Study Apr 27 2016
Biocept Continues International Expansion through Agreement with Quest Diagnostics Mexico Apr 18 2016
Biocept Continues International Expansion through Agreement with Quest Diagnostics Mexico Apr 18 2016
Biocept to Present at the 15th Annual Needham Healthcare Conference Apr 06 2016
Biocept to Present at the 15th Annual Needham Healthcare Conference Apr 06 2016
Biocept Forms Clinical Advisory Board of World-Renowned Oncologists Mar 30 2016
Biocept Forms Clinical Advisory Board of World-Renowned Oncologists Mar 30 2016
Biocept's Mark Foletta Honored with CFO Lifetime Achievement Award Mar 23 2016
Biocept to Collaborate on Biopharma Company Clinical Trial by Identifying Biomarkers Found in... Mar 21 2016
Biocept to Collaborate on Biopharma Company Clinical Trial by Identifying Biomarkers Found in... Mar 21 2016
BIOCEPT INC Financials Mar 16 2016
Biocept, Inc. :BIOC-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 14 2016
BIOCEPT INC Files SEC form 10-K, Annual Report Mar 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK